• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSivida Corp.

pSivida buys Icon Bioscience and rebrands as EyePoint Pharmaceuticals

March 29, 2018 By Sarah Faulkner

EyePoint Pharmaceuticals

With the help of $61 million from EW Healthcare Partners and a third-party investor, pSivida (NSDQ:PSDV) announced today that it acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. The two companies combined and plan to do business as EyePoint Pharmaceuticals. pSivida also landed a $20 million debt facility from SWK […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: iconbioscience, pSivida Corp.

FDA to review pSivida’s ocular drug-delivery system

March 20, 2018 By Sarah Faulkner

pSivida Durasert

pSivida (NSDQ:PSDV) said yesterday that the FDA plans to review the company’s application for its drug-releasing ocular insert, Durasert. The product is designed to provide three years of treatment for patients with posterior segment uveitis. The U.S. regulatory agency is slated to decide whether or not to approve pSivida’s new drug application by Nov. 5. “The […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

pSivida touts 12-month data from Ph3 trial of Durasert ocular insert

February 8, 2018 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) touted results today from a second Phase III trial that the company conducted for its three-year posterior segment uveitis treatment. The 153-patient study found that there was a significant reduction in the recurrence of posterior segment uveitis through 12 months in the group treated with pSivida’s drug-releasing ocular insert, Durasert. Just 37% of people […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

pSivida seeks FDA nod for 3-year treatment of posterior segment uveitis

January 8, 2018 By Sarah Faulkner

pSivida Durasert

pSivida (NSDQ:PSDV) has submitted a new drug application to the FDA for its Durasert implant that provides three years of treatment for people with posterior segment uveitis. The drug-delivery product’s NDA includes data from two Phase III trials, both of which met their primary efficacy endpoints after six months. pSivida’s Durasert product also boasts a safety […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

pSivida touts pilot osteoarthritis trial for Durasert implant

December 14, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) touted results today from a Phase I safety and efficacy pilot trial of its sustained-release Durasert implant in patients with osteoarthritis of the knee. The company’s Durasert tech, combined with an implantable device from the Hospital for Special Surgery, was designed to continuously deliver a low dose of dexamethasone into the knee joint. Six patients […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Orthopedics, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

pSivida and Nicox partner to develop sustained-release IOP drug for glaucoma patients

October 10, 2017 By Sarah Faulkner

pSivida, Nicox

pSivida (NSDQ:PSDV) and Nicox (EPA:COX) said today that the companies are collaborating to develop a sustained-release drug to lower intraocular pressure in people with glaucoma or ocular hypertension. The deal combines pSivida’s bioerodible sustained-release drug delivery system with Nicox’s nitric oxide-donating compounds. According to the agreement, pSivida is responsible for initial development activities. Nicox is slated […]

Filed Under: Business/Financial News, Featured, Optical/Ophthalmic, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: nicox, pSivida Corp.

pSivida partners for sustained-release glaucoma drugs

September 26, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) said today that it inked a deal with an unnamed global pharmaceutical company to develop two glaucoma drugs with pSivida’s sustained-release technology. The partnership includes $750,000 worth of upfront payments for initial development and the potential for $200,000 in additional payments contingent upon subsequent development activities, according to the Watertown, Mass.-based company. “A key […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

pSivida licenses European rights for Durasert to Alimera

July 11, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) said today that it restructured a deal with Alimera Sciences (NSDQ:ALIM) to grant Alimera rights to the Durasert three-year treatment for posterior segment uveitis in Europe, the Middle East and Africa. Alimera, which holds an exclusive license to pSivida’s intravitreal implant, Iluvien, plans to apply for a secondary indication for Iluvien for posterior segment uveitis. […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, pSivida Corp.

pSivida seeks European regulatory nod for Durasert

June 22, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) is looking to market its Durasert 3-year treatment for posterior segment uveitis in the European Union. Today, the Watertown, Mass.-based company submitted a marketing authorization application to the European Medicines Agency. Earlier this month, pSivida reported that its 2nd Phase III trial, which followed patients for 3 years, met its primary endpoint of […]

Filed Under: Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: pSivida Corp.

pSivida implant meets primary endpoint in late-stage trial

June 14, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) touted data from the 2nd Phase III trial of its Durasert 3-year treatment for posterior segment uveitis. The company reported that the trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months. In the 153-patient trial, 21.8% of Durasert-treated patients had a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: pSivida Corp.

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS